Specialty Pharma Journal Specialty, Precision & Technology
BERKELEY, Calif., May 16, 2016 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that the Phase 2b ECLIPSE trial did not meet the primary endpoint of an improvement in overall survival for patients with pancreatic cancer who had failed at least two prior therapies in the metastatic setting. Median …
Tag Archives: Aduro Biotech
May, 2016
March, 2015
-
30 March
Novartis Enters $750 Million Immuno-Oncology Collaboration with Aduro Biotech
Swiss drugmaker Novartis is increasing its efforts in immuno-oncology, entering a $750 million research, development and commercialization agreement with Aduro Biotech, Inc. The companies announced a collaboration for the worldwide research, development and commercialization of novel immuno-oncology products derived from Aduro’s cyclic dinucleotide (CDN) approach to target the Stimulator of …
-
26 March
FDA Grants Orphan Drug Designation to Aduro’s Mesothelioma Candidate
Today, Aduro Biotech Inc. announced that US health regulators have granted Orphan Drug designation to its novel, immuno-oncology candidate. The company said that the Office of Orphan Product Development of the US Food and Drug Administration (FDA) granted orphan drug designation to CRS-207, Aduro’s novel immuno-oncology product candidate in development …